Biology subjects

Rozov, S.

Publications and source records attributed to Rozov, S..

4 recordsLinked to original sources

bioRxiv2026

Molecular signaling associated with antidepressant actions exhibits diurnal fluctuations in the prefrontal cortex and hippocampus of adult male and female mice

An increasing number of epidemiological and experimental studies have demonstrated a bidirectional relationship between mood disorders and the circadian system, with disrupted circadian rhythms contributing to depressive states, and their restoration playing a key role in antidepressants effects. In this context, we sought to examine whether key molecular targets of antidepressants exhibit diurnal regulatory patterns. Naive adult male and female C57BL/6 mice were euthanized at 3-hour intervals beginning at Zeitgeber Time 0 (ZT0), and hippocampal (HC) and medial prefrontal cortex (mPFC) tissues were collected for RT-qPCR and western blot analyses. We observed statistically significant diurnal rhythmicity in all analyzed transcripts (cFos, Arc, Nr4a1, Dusp1, Dusp5, and Dusp6) in both HC and mPFC samples, with peak expression occurring during the dark (active) phase (ZT15-18). Phosphorylation levels of TrkBY816 (tropomyosin-related kinase) and GSK3{beta}S9 (glycogen synthase kinase 3{beta}) also showed periodic rhythmicity, peaking during the light (inactive) phase. Levels of p-ERK2T185/Y187 (extracellular-signal regulated kinase) did not display rhythmicity, but peaked during the light phase in the HC, especially in males. Collectively, these findings demonstrate that antidepressant targets are subject to diurnal regulation, highlighting the importance of integrating circadian biology and time-of-day as relevant variables in the development of translationally relevant antidepressant research. HighlightsO_LIKey molecular targets of antidepressants exhibit diurnal regulation in adult mice C_LIO_LIDiurnal patterns were conserved across targets, sexes, and brain regions (HC&PFC) C_LIO_LIcFos, Arc, Nr4a1, Dusp1,5,6 mRNAs display peak expression during the dark phase C_LIO_LITrkBY816 and GSK3{beta}S9 phosphorylation peak during the light (inactive) phase C_LIO_LIAntidepressant mechanisms may be linked with circadian and sleep-wake dynamics C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=102 SRC="FIGDIR/small/716906v1_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@1e65e60org.highwire.dtl.DTLVardef@13e302corg.highwire.dtl.DTLVardef@1ccc25forg.highwire.dtl.DTLVardef@1ed10d3_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

bioRxiv2022

Rapid-acting antidepressants ketamine and nitrous oxide converge on MAPK-DUSP signaling in the medial prefrontal cortex

Nitrous oxide (N2O; laughing gas) has recently been reported as a putative rapid-acting antidepressant, but little is known about the underlying mechanisms. We performed transcriptomics, in situ hybridization, and electrophysiological studies to examine the potential shared signatures induced by 1 h inhalation of 50% N2O and a single subanesthetic dose of ketamine in the medial prefrontal cortex (mPFC) in adult mice. Both treatments similarly affected the transcription of several negative regulators of mitogen-activated protein kinases (MAPKs), namely, dual specificity phosphatases. The effects were primarily located in the pyramidal cells. Notably, the overall effects of N2O on mRNA expression were much more prominent and widespread compared to ketamine. Ketamine caused an elevation of the spiking frequency of putative pyramidal neurons and increased gamma activity (30-100 Hz) of cortical local field potentials. However, N2O produced no such effects. Spiking amplitudes and spike-to-local field potential phase locking of putative pyramidal neurons and interneurons in this brain area showed no uniform changes across treatments. Thus, this study characterized the electrophysiological and transcriptome-wide changes in mPFC triggered by exposure to N2O and compared them with those caused by the rapid-acting antidepressant ketamine in terms of both the direction of their regulation and localization.

pharmacology and toxicology↗

bioRxiv2021

Physiological basis underlying antidepressant-induced activation of TrkB receptors

We show that both pharmacological and non-pharmacological treatments of depression activate TrkB receptors--a well-established target of antidepressants--by inducing a physiological response coupled to sedation. Several rapid-acting antidepressants trigger TrkB signaling by evoking a state associated with electroencephalographic slow-wave activity, behavioral immobility, reduced cerebral glucose utilization, and lowered body temperature. Remarkably, antidepressant-induced TrkB signaling was not compromised in animals exhibiting reduced activity-dependent release of BDNF but was diminished by maintaining animals in warm ambient temperature. Most importantly, prevention of the hypothermic response attenuated the behavioral effects produced by rapid-acting antidepressant nitrous oxide. Our results suggest that the phenomenon underlying TrkB transactivation--changes in energy expenditure and thermoregulation--is essential, but not sufficient, for antidepressant responses. Indeed, regardless of differential clinical and pharmacodynamic properties, all drugs that disrupt energy metabolism and induce hypothermia activated TrkB. This study challenges pharmacology-centric hypotheses regarding antidepressant effects and highlight the role of complex changes in bioenergetics and thermoregulation. HighlightsO_LIRapid-acting antidepressants evoke homeostatic emergence of slow-wave sleep during which TrkB signaling becomes regulated. C_LIO_LINon-antidepressant metabolic inhibitors and diverse sedatives activate TrkB signaling. C_LIO_LIReduction in body temperature determined the ability of antidepressants to transactivate TrkB. C_LIO_LIDrug-induced TrkB signaling was blunted by maintenance of normothermic body temperature. C_LIO_LIWarm ambient temperature after nitrous oxide exposure blocked the antidepressant-like effects. C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=78 SRC="FIGDIR/small/458151v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@1f7351borg.highwire.dtl.DTLVardef@bf920forg.highwire.dtl.DTLVardef@10e34eaorg.highwire.dtl.DTLVardef@1b42bb6_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

bioRxiv2017

Neurotrophin Receptor Ntrk2b Function In The Maintenance Of Dopamine And Serotonin Neurons In Zebrafish

Brain-derived neurotrophic factor (BDNF), together with its cognate receptor tyrosine kinase B (TrkB), plays an essential role in the development and plasticity of the brain and is widely implicated in psychiatric diseases (Autry and Monteggia, 2012). Due to the highly conserved evolutionary lineage of neurotrophins and their receptors in vertebrates, the zebrafish is a well-suited model for this study. The TrkB receptor, also known as NTRK2, has two forms in zebrafish, Ntrk2a and Ntrk2b. The spatio-temporal expression pattern of bdnf and ntrk2b in zebrafish was studied using in situ hybridization. The complementary expression pattern of ntrk2b to bdnf suggests that ntrk2b is the key receptor, unlike its duplicate isoform ntrk2a. Two reverse genetics strategies, morpholino oligonucleotides (MO) and the TILLING mutant, were applied in this study. The loss or complete deletion of ntrk2b had no major effect on the viability, gross phenotype, or swimming behavior of zebrafish. A specific subset of the dopaminergic and serotonergic neuronal population was affected in the morphants and mutants. Downstream signaling transcripts such as bdnf, serta, th2, and tph2 were downregulated and could be rescued by overexpression of the full-length ntrk2b mRNA in the morphants. Pharmacological intervention with a tyrosine kinase inhibitor, K252a, resulted in similar phenotypes. Overall, our results reveal a specific effect of ntrk2b on the two crucial aminergic systems involved in psychiatric disorders and provide an essential tool to study neurotrophin function in modulating neuronal plasticity in the central nervous system.\n\nSignificance StatementBrain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tyrosine kinase (TrkB/NTRK2), play a major role in regulating the development and plasticity of neural circuits. Additionally, BDNF/TrkB signaling is involved in psychiatric disorders and antidepressant responses. This study presents the complementary gene expression pattern of TrkB and BDNF in zebrafish during the early larval stage and in the adult brain. Our results consistently indicate that BDNF/TrkB signaling has a significant role in the development and maintenance of dopaminergic and serotonergic neuronal populations. Therefore, the ntrk2b-deficient zebrafish model is well suited to studying psychiatric disorders attributed to a dysfunctional monoaminergic system, and could potentially be a valuable model for small molecule drug screening.

neuroscience↗